In GHR-expressing (GHR+) cancers of breast, pancreas, colon, liver, endometrium, as well as melanoma, GH induces the process of epithelial-to-mesenchymal transition [19,20], which is a critical step in therapy evasion and invasive metastasis in tumors. Here, GH1 is linked to cancer.